Related Experiment Video
Updated: May 6, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Paediatric hepatocellular adenomas: Lessons from a systematic review of relevant literature
Isabelle Scheers1, Roberto Tambucci2, Catherine De Magnee2
1Pediatric Gastroenterology and Hepatology, Cliniques universitaires Saint-Luc. Laboratoire de Pédiatrie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium.
Insights
Paediatric hepatocellular adenomas (HCAs) often occur with predisposing diseases like glycogen storage disease. These benign liver tumours can bleed or transform, requiring management based on underlying conditions and lesion characteristics.
Area of Science:
- Hepatology
- Pediatric Oncology
- Gastroenterology
Background:
- Hepatocellular adenomas (HCAs) are rare benign liver tumors with distinct characteristics in children compared to adults.
- Understanding predisposing factors and complication rates is crucial for effective management of pediatric HCAs.
Purpose of the Study:
- To systematically characterize pediatric HCAs, including their course, complications, and management strategies.
- To investigate the influence of predisposing diseases and genetic factors on HCA development and outcomes in children.
Main Methods:
- Systematic literature review of medical history, clinical symptoms, imaging, histopathology, and genetics of pediatric HCAs.
- Inclusion of 316 children diagnosed with HCAs.
Main Results:
- HCAs were diagnosed predominantly in girls (59.3%) around age 11.5.
- 83.6% of cases were associated with predisposing diseases, most commonly glycogen storage disease, portosystemic shunts, and MODY3.
- Complications included bleeding (24.7%) and transformation (14.8%), with transformation linked to portosystemic shunts and beta-catenin mutations, and hemorrhage to hormone exposure and larger lesions.
Conclusions:
- Pediatric HCAs are often linked to underlying conditions, influencing their behavior and management.
- Management strategies involve addressing predisposing factors, surgical resection of complicated lesions, and liver transplantation for adenomatosis.
- Advances in understanding genetic contributions are key to improving HCA pathogenesis insights, patient surveillance, and treatment.
Abstract:
Hepatocellular adenomas (HCAs) are rare benign liver tumours. Predisposing factors and complication rates appear to differ among children and adults. In the present study, we aimed to systematically characterise paediatric HCAs and determine their course, complications, and management. Medical history, clinical symptoms, imaging, histopathology, and genetics of children with HCAs were collected through a systematic and comprehensive review of the published literature. A total of 316 children with HCAs were included in the present study. HCAs were diagnosed primarily in girls (59.3%) and at a mean age of 11.5 (range 0-17.7) years. The majority (83.6%) of HCAs occurred in children with predisposing diseases, of which glycogen storage disease was the most common, followed by portosystemic shunts and MODY3 (maturity-onset diabetes of the young type 3). Each of these diseases leads to a well-defined HCA molecular pattern. A significant number of HCAs either bled (24.7%) or transformed (14.8%) over time. HCA transformation was significantly more frequent in children with portosystemic shunts and in β-catenin-mutated HCAs, while haemorrhages were more frequent in children exposed to hormones and those with larger lesions. Management was primarily guided by any predisposing conditions and the number of lesions. Therefore, vascular shunts were closed when possible, while complicated lesions were resected. Liver transplantation has made it possible to treat adenomatosis, as well as any underlying diseases. Progress in understanding genetic and/or malformative contributions, which appear to be significant in paediatric HCAs, have provided insights into tumour pathogenesis and will further guide patient surveillance and management.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

